Janus Henderson Group PLC Buys 4,266,179 Shares of Applied Therapeutics, Inc. (NASDAQ:APLT)

Janus Henderson Group PLC lifted its stake in shares of Applied Therapeutics, Inc. (NASDAQ:APLT) by 198.6% during the first quarter, Holdings Channel.com reports. The firm owned 6,414,642 shares of the company’s stock after acquiring an additional 4,266,179 shares during the period. Janus Henderson Group PLC owned 0.06% of Applied Therapeutics worth $43,555,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. AIGH Capital Management LLC lifted its position in Applied Therapeutics by 109.1% in the 4th quarter. AIGH Capital Management LLC now owns 1,659,039 shares of the company’s stock valued at $5,558,000 after acquiring an additional 865,689 shares in the last quarter. Opaleye Management Inc. lifted its position in Applied Therapeutics by 22.3% in the 4th quarter. Opaleye Management Inc. now owns 1,092,500 shares of the company’s stock valued at $3,660,000 after acquiring an additional 199,500 shares in the last quarter. Vestal Point Capital LP bought a new position in Applied Therapeutics in the 4th quarter valued at about $13,919,000. Worth Venture Partners LLC lifted its position in Applied Therapeutics by 112.9% in the 4th quarter. Worth Venture Partners LLC now owns 412,981 shares of the company’s stock valued at $1,383,000 after acquiring an additional 219,008 shares in the last quarter. Finally, Jump Financial LLC bought a new position in Applied Therapeutics in the 4th quarter valued at about $81,000. Institutional investors own 98.31% of the company’s stock.

Applied Therapeutics Price Performance

Shares of Applied Therapeutics stock traded down $0.06 during mid-day trading on Tuesday, hitting $4.98. 762,541 shares of the stock were exchanged, compared to its average volume of 1,495,258. Applied Therapeutics, Inc. has a 12 month low of $1.18 and a 12 month high of $9.39. The company has a 50-day simple moving average of $4.76 and a 200 day simple moving average of $4.78.

Applied Therapeutics (NASDAQ:APLT) last posted its earnings results on Thursday, May 9th. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.09). The business had revenue of $0.19 million for the quarter, compared to analysts’ expectations of $10.00 million. On average, equities analysts predict that Applied Therapeutics, Inc. will post -0.59 earnings per share for the current year.

Insider Transactions at Applied Therapeutics

In other news, CFO Leslie D. Funtleyder sold 16,980 shares of the firm’s stock in a transaction that occurred on Thursday, June 6th. The shares were sold at an average price of $4.32, for a total transaction of $73,353.60. Following the completion of the sale, the chief financial officer now owns 291,441 shares in the company, valued at approximately $1,259,025.12. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In related news, major shareholder Real Estate Equitie Alexandria sold 150,000 shares of Applied Therapeutics stock in a transaction that occurred on Tuesday, June 4th. The shares were sold at an average price of $4.21, for a total value of $631,500.00. Following the completion of the transaction, the insider now directly owns 6,005,077 shares in the company, valued at approximately $25,281,374.17. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Leslie D. Funtleyder sold 16,980 shares of Applied Therapeutics stock in a transaction that occurred on Thursday, June 6th. The shares were sold at an average price of $4.32, for a total transaction of $73,353.60. Following the completion of the transaction, the chief financial officer now owns 291,441 shares of the company’s stock, valued at $1,259,025.12. The disclosure for this sale can be found here. Insiders sold a total of 250,778 shares of company stock worth $1,066,861 in the last quarter. Insiders own 8.60% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $12.00 price target on shares of Applied Therapeutics in a research report on Wednesday, July 17th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Applied Therapeutics has a consensus rating of “Buy” and an average price target of $11.00.

Applied Therapeutics Company Profile

Applied Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG.